Dr Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases and the US President's chief medical adviser, said on Sunday that the data needed to determine the advisability of booster shots of the Moderna Inc (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) COVID-19 vaccines is just weeks away, Reuters news agency reported on Monday.
On 17 September 2021, a US Food and Drug Administration advisory panel had recommended a third shot of the two-dose Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for people age 65 and older or at high risk of severe COVID-19, but declined to endorse boosters for the wider population.
People who have received the two-dose Moderna vaccine or one-dose J&J vaccine are still awaiting guidance on possible booster shots.
Dr Fauci added that more data may also show a broader need for booster shots across the general US population.
Health officials reportedly indicated that they expected boosters would ultimately be recommended for a broad range of the population, but urged Americans not to seek booster doses until FDA approval is received.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT